Restoration of hematopoietic function in myelofibrosis can be achieved through targeted therapy and hematopoietic stem cell transplantation. Based on the understanding of the pathogenesis of myelofibrosis and the signaling pathway, rucotinib is a targeted therapy drug developed to target this pathway, which can specifically block the abnormal signaling pathway to achieve the purpose of controlling the disease. Targeted therapy can slow down the process of myelofibrosis, prolong the survival period, improve the patient’s symptoms, reverse the disease, and then restore hematopoietic function. Therefore, patients with myelofibrosis can be treated with rucotinib if possible. Intermediate-risk and high-risk myelofibrosis patients can undergo allogeneic hematopoietic stem cell transplantation to restore hematopoietic function, but the mortality rate and complication rate associated with the treatment are quite high, and it is only for younger patients who have suitable donors and are in good general condition and tolerate it well. In case of myelofibrosis, it is recommended to go to the hospital in time for early and regular treatment.